News Releases

Date Title and Summary View
December 14, 2018
– KVD900 Enlarged Phase 2 Trial on Track for Potential On-Demand Treatment of Attacks in Patients with Hereditary Angioedema – – Intravitreal Diabetic Macular Edema Candidate KVD001 Phase 2 Trial Enrollment on Track with Completion Expected in H2 2019 – – Operations Funded into 2021 – CAMBRIDGE,...
Additional Formats
November 12, 2018
– Enlarged Phase 2 Study to Begin in 2018 for Potential Acute Treatment of Hereditary Angioedema; Data Expected in Late 2019 –
– Food Effect Study Indicates No Dosing Limitations from Food and Confirms Rapid Uptake and High Exposure –
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov....
Additional Formats
November 6, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 6, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a...
Additional Formats
September 25, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 25, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
September 14, 2018
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--
– KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema –
– Intravitreal Diabetic Macular Edema Candidate KVD001 Enrollment On Track with Data Expected in H2 2019 –...
Additional Formats
September 10, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 10, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its...
Additional Formats
September 6, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 6, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its...
Additional Formats
September 5, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 5, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer...
Additional Formats
August 7, 2018
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 7, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a...
Additional Formats
July 31, 2018
– KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema (HAE) –
– KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Enrollment Remains on Track with Data Expected in H2 2019 –
– $14.6 Million...
Additional Formats
Displaying 1 - 10 of 18